Brain-targeted, drug-loaded solid lipid nanoparticles against glioblastoma cells in culture

Area of Science:

• Nanotechnology
• Oncology
• Pharmacology

Background:

• Glioblastoma multiforme (GBM) presents a significant challenge in cancer therapy.
• Targeted drug delivery systems are crucial for enhancing the efficacy of anticancer agents.
• Monocarboxylate transporter-1 (MCT-1) is a potential target for brain tumor therapy.

Purpose of the Study:

• To prepare and characterize solid lipid nanoparticles (SLN) loaded with carmustine (BCNU) and temozolomide (TMZ).
• To incorporate targeting molecules (β-hydroxybutyric acid) for enhanced uptake by MCT-1 expressing glioblastoma cells.
• To evaluate the in vitro anticancer activity and drug release profile of the developed nanoparticles.

Main Methods:

• Preparation of SLN from cetyl palmitate.
• Characterization of SLN properties: size, morphology, zeta potential, drug encapsulation, and stability.
• In vitro drug release studies and cytotoxicity assays on U87MG glioblastoma cells.
• Assessment of nanoparticle uptake by MCT-1 expressing brain cells.

Main Results:

• BCNU and TMZ loaded SLNs demonstrated a hydrodynamic size of 227 nm ± 46 and zeta potential of -25 mV ± 4.
• Nanoparticles exhibited biocompatible features and could be stored for nine months.
• Rapid initial drug release followed by sustained release was observed.
• Loaded SLNs showed significantly enhanced antitumor activity and induced apoptosis compared to free drugs.
• Targeted nanoparticles displayed increased uptake by MCT-1 expressing brain cells.

Conclusions:

• BCNU and TMZ loaded SLNs are effective in enhancing anti-proliferation against glioblastoma multiforme.
• The developed nanoparticles serve as a promising drug delivery system for targeted GBM therapy.
• Targeting MCT-1 positive glioblastoma cells with these nanoparticles offers a potential therapeutic strategy.